miércoles, 6 de mayo de 2020

Usefulness of Ivermectin in COVID-19 Illness

Usefulness of Ivermectin in COVID-19 Illness

Links to relevant documents

Updated, July 8, 2020

Please visit the website: https://covid19ivermectin.info/

for updates on this page.

Updated, June 26 2020  



Se reporta una muy significativa disminución de la Tasa de Letalidad con su uso  
Gustavo Aguirre Chang. Médico egresado de la UNMSM, con Post Grados en Gestión y Salud Ocupacional. Lima, Perú. 2 de Mayo del 2020.

Ver Documento aquí.

Anexo 2. Plan Terapeutico
Tratamiento preventivo con Ivermectina



Updated May 8, 2020 (in Spanish).

English version: 
INCLUSION OF IVERMECTIN IN THE FIRST  THERAPEUTIC LINE OF ACTION FOR COVID-19  A very significant decrease in the Mortality Rate is reported with its use  
Gustavo Aguirre Chang. Médico egresado de la UNMSM, con Post Grados en Gestión y Salud Ocupacional. Lima, Perú. 2 de Mayo del 2020.



The existing evidence regarding the use of Ivermectin in COVID-19 is reviewed. A report is also made of the cases treated at the local level.

A study recently published in the journal Antiviral Research obtained participants from 169 hospitals around the world, this study includes a high number of patients treated with Ivermectin: 704 and their corresponding 704 controls. The study results indicate that the case fatality rate in patients who used Ivermectin was 6.1 times less compared to patients who did not use Ivermectin (1.4 vs. 8.5%, p <0.0001).

In the Dominican Republic, the Pulmonologist J. Tavares reports that he is treating 247 patients with Ivermectin with a favorable response in all cases and has not reported any fatal cases.

Similarly, at the local level, although to date there are not many documented cases, the case fatality rate has been 0% and it is also observed that in 100% of the cases treated with Ivermectin there is an improvement in the illness and resolution of fever within 48 hours of starting treatment.

A new therapeutic scheme is presented according to the degree of severity and response to treatment, prepared based on the experience of patients treated locally. In the final part, an evaluation of the Risk-Benefit of the use of Ivermectin is made, the conclusion is given that, since there is practically no risk in its use, it is recommended to formalize its inclusion in the first line of therapeutic action for COVID-19.

Finally, Recommendations are given mainly related to the supply in Health Establishments throughout the country.


Peru approves Ivermectin for COVID-19:

Modifican el Documento Técnico: Prevención, Diagnóstico y Tratamiento de
personas afectadas por COVID-19 en el Perú resolución ministerial N 270-2020-MINSA.



1. Clinical Trials

2. Scientific publications: Ivermectin as antiviral of broad spectrum

Peer reviewed: 

  • https://www.nature.com/articles/s41429-020-0336-z
    Review Article Published: 12 June 2020
    Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
    Fatemeh Heidary & Reza Gharebaghi
    The Journal of Antibiotics (2020)
  • Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.

    Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Mar 20. pii: dkaa114. doi: 10.1093/jac/dkaa114. [Epub ahead of print]
  • The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Research, Volume 177, 2020, "http://www.sciencedirect.com/science/article/pii/S0166354219307211
  • Tu, Y.-F.; Chien, C.-S.; Yarmishyn, A.A.; Lin, Y.-Y.; Luo, Y.-H.; Lin, Y.-T.; Lai, W.-Y.; Yang, D.-M.; Chou, S.-J.; Yang, Y.-P.; Wang, M.-L.; Chiou, S.-H. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int. J. Mol. Sci. 2020, 21, 2657.  https://www.mdpi.com/1422-0067/21/7/2657/htm
  •  Raza, S.; Shahin, F.; Zhai, W.; Li, H.; Alvisi, G.; Yang, K.; Chen, X.; Chen, Y.; Chen, J.; Hu, C.; Chen, H.; Guo, A. Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes With Viral Replication. Microorganisms 2020, 8, 409. https://www.mdpi.com/2076-2607/8/3/409
  • R. Choudhary, A.K. Sharma, Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance, New Microbes and New Infections, Volume 35, 2020,
  •  Angela Patrì, Gabriella Fabbrocini, Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?,
    Journal of the American Academy of Dermatology, 2020, http://www.sciencedirect.com/science/article/pii/S0190962220305570
  • Mike Bray, Craig Rayner, François Noël, David Jans, Kylie Wagstaff,
    Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Research, 2020, http://www.sciencedirect.com/science/article/pii/S0166354220302199 
"Ivermectin’s key direct target in mammalian cells is a not a viral component, but a host protein important in intracellular transport (Yang et al., 2020); the fact that it is a host-directed agent (HDA) is almost certainly the basis of its broad-spectrum activity against a number of different RNA viruses in vitro (Tay et al., 2013; Yang et al., 2020). The way a HDA can reduce viral load is by inhibiting a key cellular process that the virus hijacks to enhance infection by suppressing the host antiviral response. Reducing viral load by even a modest amount by using a HDA at low dose early in infection can be the key to enabling the body’s immune system to begin to mount the full antiviral response before the infection takes control."

  • Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, Volume 178, 2020, http://www.sciencedirect.com/science/article/pii/S0166354220302011
  • Hiroshi Maruta, Hong He, PAK1-blockers: Potential Therapeutics against COVID-19, Medicine in Drug Discovery, Volume 6, 2020,
  • Kylie M. WAGSTAFF, Haran SIVAKUMARAN, Steven M. HEATON, David HARRICH and David A. JANS Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus Biochem. J. (2012) 443, 851–856. doi:10.1042/BJ20120150
  •  Lucia Romani, Ph,D. Michael Marks, PhD Oliver Sokana, MPH Titus Nasi, MCHBakaai Kamoriki Billie Cordell, MPH  Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. The Lancet. Volume 19, ISSUE 5, P510-518, May 01, 2019   https://doi.org/10.1016/S1473-3099(18)30790-4 
  • Crump, A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot 70, 495–505 (2017). https://doi.org/10.1038/ja.2017.11
Antiviral: "Ivermectin has also been demonstrated to be a potent broad-
spectrum specific inhibitor of importin α/β-mediated nuclear trans-
port and demonstrates antiviral activity against several RNA viruses by
blocking the nuclear trafficking of viral proteins. It has been shown to
have potent antiviral action against HIV-1 and dengue viruses, both of
which are dependent on the importin protein superfamily for several
key cellular processes. Ivermectin may be of import in disrupting
HIV-1 integrase in HIV-1 as well as NS-5 (non-structural protein 5)
polymerase in dengue viruses"

2.  Testimonials from Medical Doctors

  • Ivermectina, La fase en que deben ser tratados los pacientes con dicho tratamiento https://youtu.be/tw1hDAiwZQQ

    • Entrevista al Dr. Tavárez Capellán - Ivermectina para tratar COVID-19

    • Entrevista al Dr. Maguiña, Ivermectina contra COVID-19?.

3.  General articles in international press



No hay comentarios.: